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Summary 
 
One important hallmark of malignant tumors is the ability to invade through 
anatomical barriers. Cancer cells invade by remodeling and moving through the 
extracellular matrix (ECM), a biomaterial that provides physical support to tissues. 
ECM remodeling and cancer cell invasion are the initial steps that lead to metastasis, 
the spread of cancer to distant organs. 
Metastasis is responsible for over 90% of cancer patient deaths [1]. 
Metastatic treatments are limited, and there is a crucial need to find new ways to 
combat cancer in general and metastasis in particular. Oral cancer patients with lymph 
node metastases have a particularly poor prognosis, thus it would be useful to identify 
changes to the lymph node (LN) that occur prior to obvious metastasis. In this study, I  
used a mouse model of oral cancer (OSCC) and identified structural remodeling that 
takes place in the neck LN before the arrival of cancer cells. The aim of this project is 
to characterize some of the changes taking place in the neck LNs which drain the 
tongue xenografts in a OSCC model, prior to the development of large colonisations 
within the LNs; in other words, attempting to characterize the pre-metastatic changes 
occurring in the lymph nodes. Specifically, I have performed immunofluorescence 
(IF) staining of the first and second draining lymph nodes for B220 as a B-cell 
marker, ER-TR7 as a fibroblast marker, CD31 as a blood vessel marker, collagen IV 
as a structural marker, fibronectin as a reticular network marker and MECA-79 as an 
high endothelial venules marker (HEVs). I have found that there is an increase in the 
number of the blood vessels of draining LNs, indicating an increase in angiogenesis. 
Also, the staining of MECA-79 showed a significant increase of the high endothelial 
venules of the same draining LNs.  
The results of this study, together with further research that would lead to a 
better understanding and clearer view of the remodeling of the LNs have a high 
potential to impact on oral cancer patient treatment.  
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1 Introduction – theoretical background  
1.1 Oral Squamous Cell Carcinoma 
 
Cancer is one of the leading causes of mortality worldwide. There was an 
estimate of 14.1 million new cases and 8.2 million cancer related deaths in 2012 and 
an increase to 22 million annual cancer cases is expected within the next 2 decades 
[2]. As oral cancer is in focus in the work presented here, it deserves a short 
introduction.  
Oral squamous cell carcinoma (OSCC) is the eighth most common cancer in the 
world. It can arise anywhere in the mucosa of the oral cavity, but mostly it occurs in 
the tongue. [3,4]. The main established risk factors are tobacco use and excessive 
alcohol consumption, but viral infection, chronic inflammation and also patient's 
genetic predispositions are classified in the high factors [5,6]. In Asia the habit of 
chewing betel quid is also a risk factor, mainly leading to cancers in the buccal 
areas[3]. 
More than 300,000 new cases of oral squamous cell carcinoma was 
diagnosed in 2012 world-wide, accounting for 2.1% of all cancer cases. Strikingly, 
men are almost twice as likely as women to be diagnosed [7], and while the reason for 
this is uncertain, culturally increased exposure to risk factors such as tobacco and 
alcohol is likely a factor. The Danish population has the highest overall incidence of 
OSCC in Northern Europe, and the same skewing of incidence is present here with 
men having an age-standardised rate of 7 out of every 100,000 men, while only 4 out 
of every 100,000 women will get OSCC each year (figure 1.1)[7].  
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Figure 1.1-OSCC incidence and mortality in Northern Europe ASR (W): age-
standardised rate. A rate is the number of new cases or deaths per 100 000 persons per year. An age-
standardised rate is the rate that a population would have if it had a standard age structure. 
Standardisation is necessary when comparing several populations that differ with respect to age 
because age has a powerful influence on the risk of cancer. Graph reproduced from online analysis on 
GLOBOCAN 2012 (www.globocan.iarc.fr)[7] 
 
 
1.2 Lymph nodes and lymphatic architecture 
 
The lymphatic system forms a second circulatory system and it is responsible 
of collecting excess interstitial fluid from the tissue and returning it to the venous 
system. It is an essential part of the immune system. The lymphatic system begins as 
blunt ended initial lymphatic capillaries within the tissue, and these connect into 
collecting lymphatic vessels that then lead the collected lymph into lymph nodes 
(LNs) [8, 9]. The lymphatic capillaries are composed of lymphatic endothelial cells 
(LECs), which adhere to each other in specialized button like cell-cell junctions [10, 
11], compared to the continuous zipper-like junctions between LECs in the bigger 
collecting lymphatics [11]. In addition the lymphatic capillaries have interrupted 
basement membrane [12, 10] and the LECs are attached to the surrounding 
extracellular matrix (ECM) [10] (figure 1.2A). Penetration of immune cells such as 
dendritic cells (DCs) from the tissue into the lymphatics happens in these initial 
lymphatics, with the cells expanding the existing portals in the interrupted basement 
membrane, and draining themselves between the LECs in spots where they lack the 
continuous zipper-like cell-cell junction [12]. Early lymphatics can be recognized 
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from collecting lymphatics by their appearance of the surface marker lymphatic vessel 
endothelial hyaluronan receptor 1 (LYVE-1) [13], a truth that is being put to use in 
research of  lymphangiogenesis. 
The greater collecting lymph vessels are encircled by a continuous basement 
membrane and smooth muscle cells (SMCs), and have intraluminal valves that 
prevent retrograde flow of lymph. Bringing together lymphatics converge into 
afferent lymphatic vessels (ALVs) that drain into the subcapsular sinus (SCS) of LNs 
[8] (figure 1.2A). The SCS is padded with sinus-lining cells and a basement 
membrane, making it a closed off compartment where from no fluid can enter into the 
lymphoid compartments of the LN. Within the SCS resident macrophages filter out 
fragments from the lymph before it is shunted to the efferent lymphatic vessel in 
hilum of the LN (figure 1.2B). In this manner the larger part of the incoming lymph is 
directly shunted onward on in the lymphatic system to finally empty out in the 
subclavian vein. But not all of the lymph gets out through the efferent lymphatic 
vessel, some comes into the conduit system of the LN. This conduit system is made of 
fibres of collagen I and other ECM proteins of a tightly regulated diameter, encased in 
a basement membrane. The collagen fibres and the basement membrane is laid down 
by fibroblastic reticular cells (FRCs) that also cover their cytoplasm completely 
around the conduits, and together the FRCs and their conduits build up what is known 
as the reticular network [14] (figure 1.2C). The close control of the collagen fibres 
and the overall diameter of the conduits impede bigger elements of the lymph such as 
cells or pathogens from entering them, letting only smaller molecules such as 
chemokines and growth factors from the incoming lymph, or produced by the FRCs, 
to be transported throughout the conduits. The FRCs head the conduit network to join 
around specialised high endothelial venules (HEVs), where the fluid and its molecular 
mass is drained into[15]. These HEVs are the entry place of circulating immune cells 
into the LN, and incoming chemokines from the conduit born lymph is rapidly stored 
on the abluminal and luminal surfaces of the HEVs [15], heading to lymphocyte 
recruitment to and extravasation from the HEV and into the LN stroma. From this 
place incoming B- and T-cells move through the FRCs to their respective 
compartments within the LN [16], which are distinctly bounded by the reticular 
network. The T-cell area in the paracortical region of the LN is characterised by a 
tight reticular network, which suddenly turn in to a very dissipate network in the 
cortical B-cell follicles [16]. DCs can also move through FRCs, and more 
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significantly they sit along the reticular network in the medullary region of the LN, 
and send cytoplasmic processes out in between the FRCs and into the conduits, to 
sample antigens from the incoming lymph [14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 - Architecture of the lymphatic system A. Initial lymphatics collect the lymph 
from the tissue, and then converge in to pre-collector and since collector lymphatic vessels. These then 
become afferent lymphatic vessels, which empty out into the subcapsular sinus of a lymph node. Once 
filtrated through the lymph node the lymph is eventually returned to the venous system via the 
subclavian vein. Figure reproduced from [9]. B. A schematic representation of the lymph node 
illustrating the sharp division of lymph and lymphoid compartments. Figure reproduced from [14]. C. 
A schematic representation of the conduit system within the paracortical and cortical region of the 
lymph node. Reproduced from [14]. 
 
 
1.3 Metastasis and lymphatic metastasis  
 
The number of cancer related deaths and the lack of metastasis treatment 
speak for themselves; there is a crucial need to find new ways to treat cancer. To do 
so, it is important to understand the underlying process of cancer initiation, growth 
and metastasis. Cancer manifests from host derived cells carrying oncogenic and 
tumor suppressor mutations, allowing them to proliferate in an uncontrolled and 
chronic manner. The complex transition where normal cells evolve into a neoplastic 
state is multistep process. Throughout this process, the evolving cancer cells acquire 
multiple capabilities that enable tumor growth and metastatic dissemination [17]. 
These capabilities have been characterized by Hanahan and Weinberg as  “the 
Hallmarks of cancer” (figure 1.3). These hallmarks attempt to describe an organizing 
principle of the abilities that are acquired for cells to become neoplastic, an important 
knowledge when searching for new cancer treatments.  
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Figure 1.3: The hallmarks of cancer. Overview of the cancer cell capabilities that enable 
tumor growth and metastasis. Figure from Hanahan and Weinberg, 2011 [17]. 
The hallmarks include the ability to metastasise. The metastatic process is 
generally regarded as a sequential occurrence of different steps, with invasion of the 
extra cellular matrix around the primary tumour being the first one (figure 1.4). The 
next step is intravasation into either the blood stream causing hematogenous 
dissemination, or entry into lymphatic vessels leading to regional spread to draining 
lymph nodes. Surviving in the bloodstream is harsh for circulating tumor cells 
(CTCs), as they must endure velocity-induced shear forces, a lack of substratum and 
the presence of immune cells. To protect themselves, the CTSs form emboli via 
interactions with blood platelets [18]. The platelet coats effectively provide a shield to 
protect of the immune cell otherwise bound on eliminating the cancer cells [19].  
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Figure 1.4: The invasion-metastasis cascade. Invasive tumor cells spread in the body and colonize 
distant tissue through a series of complex biological events. The tumor cells invade into adjacent tissue, 
intravasate into the bloodstream and circulate before they arrest at distant organs and extravagate out of 
blood vessels. At the distant tissue, the single tumor cells form micro-metastases, which can grow into 
macro-metastases. Figure from Valastyan and Weinberg, 2011 [18]. 
 
Even though, the seminal work by Luzzi et al has shown just how inefficient 
the metastatic process is in general, with an estimated <0.01% CTCs forming macro-
metastases [20], metastasis is still the primary cause of cancer deaths [1].  So far 
several biomarkers for metastasis and CTCs have been discovered [18].  
Unfortunately, the discovery of effective anti-metastatic therapeutics is lagging 
behind, and research in understanding the mechanisms of metastatic spread and 
preventing dissemination and metastatic growth of cancer cells is very important. 
 
1.4 Lymphatic metastasis - gateway to distant metastasis? 
 
OSCC easily propagates to the regional neck lymph nodes, which is reflected 
in the fact that nearly 50% of all new cases in the US are diagnosed with regional 
spread [22]. Lymphatic metastasis has been considered as a result of the anatomy of 
the lymphatic system, with cancer cells passively going with the flow and getting 
immobilized in the downstream LNs. The anatomy of the lymphatic capillaries, 
including punctuate cell-cell junctions between the LECs[11] and a interrupted 
basement membrane[12, 10], may have tumours cells with an easier route of 
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propagation than entry into the blood stream. Moreover, they do not need to protect 
themselves against great shear stress forces as the lymphatic system is a low pressure 
circuit. Newly a new cover has been added to the story, with cancer cells hacking 
homing systems normally employed by immune cells, targeting them for entry into 
the lymphatics.  
In carcinomas and melanomas the existence of nodal metastasis is a strong 
indicator of distant metastasis [22, 23, 24], and it is a continuing discussion whether 
nodal metastasis precedes distant spread, or if it is just a sign of aggressiveness of the 
disseminated tumour cells [24]. Studies recommend that at least in some cancer types 
there is a sequential way of spreading, with LN metastasis being the first step [25, 
26]. 
It is a compelling conception that cancer cells following in growing in the 
LN may be selected for clones suited for growth in foreign locations. This could in 
turn result in cancer cells spreading from LN metastases being more able of 
colonizing other more distant areas, effectively designating the LN as a training camp 
for strong new soldiers. Also the tumour cells at the start have to get bigger in the 
LNs before they can lastly break with their new powers. As pointed out above this is a 
rate limiting step in metastasis, which was found to depend on the microenvironment 
the spread cells arrive at [27]. Paget suggested the seed and soil hypothesis, claiming 
that cancer cells will grow in permissive foreign areas like seeds in congenital soil 
[28]. Proof suggesting that the initial tumour is actively making ready distant 
locations for the arrival of tumour cells, producing pre-metastatic niches, is emerging, 
and among these lymphangiogenesis and vascular re-organization in LNs draining 
tumours, but free of metastases, have been reported[29, 30, 31, 32, 26, 33]. Tumour 
produced, pre-metastatic lymphangiogenesis in mice extended the risk of later 
developing nodal[29] and distant metastases[30], indicating that the pre-metastatic 
remodeling happening in LNs could help to build a more friendly environment for the 
continuously disseminating tumour cells to get bigger and develop within. 
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2 Aims 
 
 
It is well recognized that structural changes occur in reactive LNs, such as 
the physiological hyperplasia occurring during immunization [38], and recently  
researchers identified that vascular and lymphatic changes also occur in LNs draining 
tumours even before the presence of metastasis  [34, 31, 33, 35, 29, 32, 36, 37]. The 
aim of this project is to characterize some of the changes taking place in the neck LNs 
which drain the tongue xenografts in a OSCC model, prior to the development of 
large colonisations within the LNs; in other words, attempting to characterize the pre-
metastatic changes occurring in the lymph nodes, by performing immunofluorescence 
staining of the first and second draining lymph nodes for B220 as a B-cell marker, 
ER-TR7 as a fibroblast marker, CD31 as a blood vessel marker, collagen IV as a 
structural marker, fibronectin as a reticular network marker and MECA-79 as an high 
endothelial venules marker. 
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3 Materials 
 
3.1 Buffers  
 
TBS/T 
Tris-buffered saline (TBS): 20mM Tris, 150mM NaCl, pH 7.6. 0.05% v/v 
Tween20 was added to create TBST. 
Combined IF permeabilisation and blocking buffer  
Immunofluorescence (IF) buffer intended to permeabilise cell membranes 
(TritonX-100) to allow access of the primary antibody to its epitope, and 
simultaneously to decrease the background by blocking any endogenous receptors 
(e.g. Fc receptors) for the secondary antibody (goat serum).  
5% v/v goat serum + 0.5% v/v TritonX-100 in TBS..  
 
IF antibody dilution buffer 
0.05% w/v Bovine Serum Albumin (BSA) in TBST  
 
3.2 Antibodies  
 
Table 1.1 – Primary antibodies 
 
Antigen Target Host Supplier Catalogue no. Usage 
Collagen IV Mouse Rabbit Millipore AB756P IF 1:200 
CD31 Mouse Hamster Thermo Scientific MA3105 IF 1:100 
ER-TR7 Human, Mouse Rat Santa Cruz 73355 IF 1:100 
Fibronectin-
Biotin 
Human, 
Mouse Rabbit Abcam Ab6584 IF 1:100 
B220 Human, Mouse Rat BioLegend 103202 IF: 1:200 
*Alexa 
Fluor 488 
MECA-79  
Human, 
Mouse Rat eBioscience 53-6036-80 
IF 1:200 
 
* fluorochrome conjugated 
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Table 1.2 – Secondary antibodies 
 
Name Supplier Catalogue no. Usage 
Alexa488 goat anti-rat IgG Invitrogen A11006 1:500 
Alexa555 donkey goat anti-
rabbit IgG Invitrogen A21070 1:500 
Alexa633 Streptavidin* Invitrogen S11223 1:500 
Alexa546 goat anti-armenian 
hamster 
 
Jackson 
Immuno 
Research 
127-295-160 1:500 
* Biotin  
 
4 Methods 
 
4.1 Microwave assisted Immunofluorescence  
 
This method is modified from [39], respectively reducing the time spent on 
performing immuno-fluorescence (IF) to around 3hrs in total for up to 12 slides, and 
with multiple sections per slide the total amount processed can be increased. In the 
following description a notation in italics signifies microwave off (e.g 1-1-1 min, 
indicates 1 min on - 1 min off - 1 min on), in the microwave at a specified Wattage 
(W). Antibody dilutions are listed in table 1.1 and table 1.2.  
 
4.1.1 OCT embedding and cryosectioning of tissue 
A metal cylinder with isopentane was place within a slurry of 96% EtOH and 
dry ice, effectively cooling the isopentane to around -70oC. The tissue to be embedded 
was placed in a plastic mould, which was then cooled with liquid OCT, and the mould 
was submerged in the cold isopentane for 1 min to snap freeze the tissue block. The 
OCT blocks were then kept at -80oC until they were sectioned.  
The tissue blocks were equilibrated to -20oC before sectioning was started to 
minimise crumbling of the tissue due to shattering of the OCT. Cryosectioning was 
carried out on a Leica CM3050- S microtome at -20oC, with a knife angle of 3-5%, 
and in 10µm thick sections unless otherwise mentioned. The sections were adhered to 
SuperFrost or SuperFrost PLUS slides and kept at -20oC for short term storage, or at -
80oC for long term storage.  
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4.1.2 Immunofluorescence (IF) of frozen sections  
 
Immunofluorescence (IF) is a powerful technique that utilizes fluorescent-
labeled antibodies to detect specific target antigens. There are two types of IF 
techniques, direct and indirect. Both are used in this project. In direct IF a specific 
primary antibody which is linked to a fluorochrome or an enzyme is used for binding 
to the target structure and visualize directly (e.g. MECA79). Indirect IF involves two 
steps, first a specific primary antibody recognizes the target structure and then a 
fluorochrome-coupled secondary antibody is applied which specifically binds to the 
primary antibody (e.g. CD-31, Collagen IV, Er-TR7, B220). This specificity is 
obtained by directing the secondary antibody against the species in which the primary 
antibody was raised, except Biotin-Streptavidin interaction (e.g. Fibronectin). 
Fluorescence microscope is used for visualization [40]. 
Frozen sections were brought to RT, then fixed in 4% PFA in a coplin jar 
placed within a container full of water by microwaving 1.5 min at 270W. After 
washing in TBST 3 x 1 min at 270W a hydrophobic circle was drawn around the 
sections using a DAKO-pen. Next, a combined permeabilisation and blocking buffer 
was added to the sections and these were placed in the incubation set-up (a tip box 
full of water, to create a humid environment), and microwaved 1-1-1 min at 270W. 
After a quick dip in TBST the primary antibody was added, and the slides were 
placed in the incubation set-up and microwaved 3-2-3-2-3 min at 270W. After 
washing in TBST 3 x 1 min at 270W, the fluorophore-conjugated secondary antibody 
was added and the slides incubated in the microwave 3-2-3-2-3 min at 270W. 
Following washing 3 x 1 min in TBST at 270W, 1µg/ml DAPI was added to the 
sections and they were left to incubate 10 min on the bench in the incubation set-up, 
covered in foil. After 1 min wash in TBST at 270W excess liquid was wiped off of 
the slides and cover slips were mounted using DAKO fluorescent mounting media 
DAKO, cat. S3023), and the slides were kept dark at 4C until they were imaged.  
 
 
 
 
 20 
4.2 Imaging  
 
4.2.1 DeltaVision 
IF labelled sections were imaged using a DeltaVision microscope set-up with 
an Olympus IX71 microscope connected to a Photometrics CoolSNAP HQ2 camera, 
using a LED light source from Lumencor. The set-up included an automatic stage, 
facilitating automatic tiling. Green fluorescence from Alexa488 fluorophores was 
excited with light through a band-pass BP 475/28 filter, and collected with a BP 
523/36 filter. Red fluorescence from Alexa633/eFluor660 conjugated antibodies was 
imaged with a Cy5 excitation filter (BP 632/22) and emission collected with a BP 
676/34 filter. DAPI nuclei counter-stain was excited through a BP 390/18 filter and 
emission collected with a BP 435/48 filter.  
Sections were imaged using a Olympus 10X/0.40NA, U-Plan S-APO 
objective, and each individual image taken in the tiling mode were stitched into one 
image. All image recording and stitching was done using the softWorx 5.5.1 software.  
 
 
4.2.2 Image analysis in ImageJ 
Quantification of IF markers in draining lymph node (drLN) sections 
The total area of the section was calculated from the DAPI stained area. 
Briefly the triangle method of thresholding was used to create an overlay that covered 
the entire LN section, based on the DAPI signal, and the thresholding was fitted 
manually to cover the entire section. The area covered by the marker of interest, e.g. 
B220, was similarly calculated from the thresholding on the channel containing the 
marker signal. This time the default method of thresholding was used to outline the 
marker covered area.  
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4.2 Statistical Analysis 
All statistical analysis were done by using GraphPad Prism 6. Kruskall-
Wallis test was used to compare nonparametric data and using Dunn’s test did 
correcting for multiple comparisons.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 : ImageJ masking for IF quantifcation A. B220-stain used for B-cells. B. 
Fibronectin staining of the reticular network. C. DAPI- staining used to determine total section 
area. Section of a tumour drLN 3 days after xenografting. 
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Results 
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5 Results 
5.1 Lymph node remodelling 
SASL1m was successfully implanted orthotopically into the tongue of BALB/c-nude 
mice by Freja Venning in our lab, and I investigated the nature of the changes that 
occur in tumour draining LNs before obvious metastasis. I compared the healthy LNs 
of a BALB/c-nude mouse to day 3 and day 9 after xenografting the same strain of 
mouse. To correct for distributional differences throughout the LN, multiple sections 
from each LN was stained, spanning at least 800µm of the LN. 
 
Looking at the percent area covered by ER-TR7 reticular marker (figure 3.3), a non-
parametric Kruskall-Wallis test comparing the means of the healthy and tumour 
drLN, both first and second LN, finds a small but non-significant difference between 
them. We observed a reduction in the ER-TR7 staining, thereby indicating the less 
reticular networking in the second draining LNs. Interestingly, there is not a big 
difference between the healthy and the first LN after day 3 of xenografted mouse. If 
we evaluate qualitatively the images of the different drLNs, a distributional difference 
becomes apparent over time.  
 
In healthy LN the collagen IV staining indeed visualises vessel structure of varying 
size, as can be seen in figure x, where the red signal outlines large vessel structures in 
the medulla of the LN, and smaller capillaries throughout the rest of the LN, including 
within the lymphoid follicles. Comparing the collagen covered area percentage across 
the different types of LN, the area of the drLNs is decreased, indicating a decrease in 
the reticular network and/or a decrease in vessels other than lymphatic capillaries, 
likely blood vessels, when tumour is drained. However, this decrease is not 
statistically significant.  
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Figure 3.1 A. Representative IF images of the different drLNs showing ER-TR7(green, middle) and 
collagen IV(red, left), DAPI(blue) covered areas,  and  all of them merged in the right panel. B. 
Quantification of ER-TR7 covered area in percent of total LN section stained. A Kruskal Wallis test finds 
no significant differences between any of the six conditions. C.  Quantification of collagen IV area. A 
Kruskal Wallis test finds no significant differences. For B and C each data point represents a different LN 
section from three different healthy mice, day 3 and 9 xenografted mice.  
  B    C 
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*
Figure 3.2 A. Representative IF images of the different drLNs showing CD31(red, left) and MECA-79(green, 
middle), DAPI(blue) covered areas,  and  all of them merged in the right panel. B. Quantification of CD31 covered 
area in percent of total LN section stained. A Kruskal Wallis test across the different conditions singles out the 
drLN2 from Day3 as having more CD31 covered area than the healthy LNs C.  Quantification of MECA79 area. 
A Kruskal Wallis test finds that there is a significant difference between drLN1 from day3 in comparison to the 
healthy LNs. For B and C each data point represents a different LN section from three different healthy mice, day 
3 and 9 xenografted mice. 
  B     C 
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CD31 is a marker found in the junction between endothelial cells in blood vessels 
[47]. My results show that there might be an increase in drLN, especially in the 
second one of day 3 after xenografting, as there is a higher intensity of staining. 
(figure 3.2). CD31 positive cells in 2ndary LN, indicating that there is an increase in 
angiogenesis. There is no significant difference within the other categories.  
Furthermore, staining of MECA79, a high endothelial venules (HEVs) marker which 
are the specialized postcapilarry venules found in lymphoid tissues that support high 
levels of lymphocyte extravasation from the blood, show/indicate that there is an 
increase and a high difference between the healthy LN and the draining ones. I 
noticed that the blood vessels tend to increase in number from the very first LN of day 
3 after xenografting. These data show that there are some pre-metastatic changes 
present within the LN of oral squamous cell carcinoma. These changes would favor 
tumor cell arrival.  
 
Lastly, staining of B-cell marker, B220, could help me see whether the lymphoid 
follicles exist underneath the reticular network, marked by Fibronectin staining, or if 
they have dispersed. However, I did not see any particular differences in B220 
staining of the different types and time points of the LN, although the difference is 
highly visible (figure 3.3A), I believe this is due to the poor quality of the images. The 
quantitative approach for Fibronectin staining shows a difference between the healthy 
and the first draining LN of day3, although it is not statistically significant.  
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Figure 3.3 A. Representative IF images of the different drLNs showing B220 (green, middle) and Fibronectin 
(red, left), DAPI(blue) covered areas,  and  all of them merged in the right panel. B. Quantification of B220 
covered area in percent of total LN section stained. A Kruskal Wallis test finds no significant differences between 
any of the six conditions. C.  Quantification of Fibronectin area. A Kruskal Wallis test finds no significant 
differences. For B and C each data point represents a different LN section from three different healthy mice, day 3 
and 9 xenografted mice.  
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6  Discussion 
6.1 Lymph node remodelling 
In this study, I investigated the structural changes that occur in the neck 
draining LNs after implanting SASL1m cells into the tongue of mice at 3 and 9 days 
after xenograft as it has been shown that there are pre-metastatic changes occurring in 
the lymph nodes before the arrival of the cancer cells [34, 31, 33, 35, 29, 32, 36, 37].  
Firstly I looked at the reticular marker ER-TR7 [42] as the reticular network 
functions to compartmentalise the LN into discrete areas with different functions, 
such as the T-cell zone and the lymphoid follicles [44, 43, 14]. Furthermore the 
network acts as a conduit system for soluble compounds such as chemokines and 
growth factors [43, 14], and thus a change in this system could indicate a change in 
the functional cross-talk between cell populations within the LN. Looking at the 
percent area covered by ER-TR7 reticular marker (figure 3.1), a non-parametric 
Kruskal-Wallis test comparing the means of the healthy and tumour drLN, both first 
and second LN, finds a small and non-significant difference between them. If we look 
qualitatively at the images of the different drLNs, a distributional difference becomes 
apparent. In healthy LNs the reticular network respects the borders of the lymphoid 
follicles, making the latter very visible from just the lack of ER-TR7 stain (figure 
3.1). In the tumour draining LN these follicles are no longer clearly discernible along 
the cortical region of the LN, and only a few areas in this region remain free of ER-
TR7 structures (figure 3.1), suggesting a global reaction within the LN. 
Collagen IV is an integral component of the basement membrane surrounding 
epithelial sheets such as the endothelia in blood vessels. Due to continuous basement 
membrane around these vessels they are visualised by collagen IV staining, whereas 
vessels with fenestrated or discontinuous basement membranes, such as lymphatic 
capillaries [10] only show weak or no collagen IV positivity. In healthy LN the 
collagen IV staining indeed visualises vessel structure of varying size, as can be seen 
in figure, where the red signal outlines large vessel structures in the medulla of the 
LN, and smaller capillaries throughout the rest of the LN, including within the 
lymphoid follicles. Collagen IV also co-localises with ER-TR7 in most places (yellow 
in merged images in figure 3.1), since collagen IV is also found within the reticular 
network, both as a basement membrane surrounding the conduits and on the outside 
of FRCs [45] and as such collagen IV stain also reveals the lack of lymphoid follicle 
boundaries in the tumour draining LN. Comparing the collagen covered area 
percentage across the different types of LN, the area of the drLNs is decresed, 
indicating a decrease in the reticular network and/or a decrease in vessels other than 
lymphatic capillaries, likely blood vessels, when tumour is drained. However, these 
decrease is not statistically significant.  
High endothelial venules (HEV) have been recognized to play a role in metastasis by 
its changes seen in the cancer microenvironment of lymph nodes and solid cancers. 
HEV are specialized post-capillary venules found in lymphoid tissues, located mainly 
in the T-call zones such as the para-cortical areas of LN. Primary tumours can induce 
vasculature reorganization within the first LN, so called sentinel LN, before the 
arrival of tumor cells and HEV represents one of these remodelled vessels. 
Researchers have been demonstrating that lymph nodes are transformed by the 
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primary tongue tumor to become a functional blood vessel-enriched organ before and 
independent of metastasis, making the HEV to become main blood flow carrier in the 
lymph node [37]. Our data support these findings as we can clearly see a significant 
difference for the sentinel LN at day3 (figure 3.2). Although, we will need more data 
points in order to have a solid and valid conclusion. However, based on our and 
mainly others researchers findings, the metastatic tumor vasculature in lymph nodes 
consists of many large blood vessels derived from normal HEVs, suggesting that the 
efficiency of nutrition and oxygen supplies could be better for the metastatic tumor 
cells in the involved lymph node. The enrichment of the blood supply in the lymph 
node before and after metastasis may favor the growth of newly arriving metastatic 
cancer cells. [46,48].  
Furthermore, the staining of CD31 which is an endothelial marker, therefore CD31 
positive structures are interpreted to be blood vessels, also suggested an increase in 
the blood vessels mainly in the second lymph node at day 3. CD31 expression seems 
to be either higher or more condensed in some vessel structures, as the cross section 
of larger vessels have a higher intensity of staining (figure 3.2). This is in line with a 
previous study reporting weaker CD31 expression in LECs than in blood endothelial 
cells (BECs) [49]. Further analysis into the number of blood vessels per area would be 
the next step in the quantitative analysis.  
The methodology used in this study to quantify the results is subject to several 
pitfalls. First is the selection bias. Considering the different size and tortuosity of the 
vessels, one histologic section in a single plane might not represent the accurate status 
of all vessels within the LN. Furthermore, misinterpretation could be the problem as a 
result of the different intensity of the staining and the complexity of the vasculature. 
Therefore, developing a better and more precise quantification method is essential. 
GAP analysis described by Acton et al in their study could be a method to adapt in 
our studies [50]. 
Future experiments and perspectives include staining of more samples from different 
mice and including a few more other markers, e.g. LYVE-1 which would give an 
overview over the lymphatic vessels. Also, a study of samples from oral cancer 
patients is taken into consideration next in our lab. 
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7 Conclusion  
In this study, I investigated some of the changes that take place in the neck 
LNs which drain the tongue xenografts in a OSCC model, by performing IF staining 
for different markers. The early morphological changes in tumor draining LNs 
described in this study might represent a switch toward a more immunosuppressed 
environment which can support the growth of incoming tumour cells. Especially the 
encroachment of the FRCs and the reticular network on the cortical regions of the LN 
suggest that this could be the case. Further research and investigation in this subject, 
could have a high impact on oral cancer patient treatment.  
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